Text Size: A- A+ Facebook Twitter LinkedIn YouTube

Breaking News

YouTube

SEARCH NEWS

Format: 04/17/2014
Format: 04/17/2014

News

Med Page Today: Novel Oral Agent Improves Pulmonary HTN

Saturday, August 31st, 2013

The novel dual endothelin-receptor antagonist macitentan (Opsumit) improved clinical outcomes in pulmonary arterial hypertension (PAH), the SERAPHIN trial showed.

To read more, visit the Med Page Today website.
 

X
West Penn Allegheny Health System
Tell us who you are:

What areas do you use on our website?*
(select more than one if it applies)











Did you find what you were looking for?


Would you refer others to our website?

Can we contact you for future questions?

CAPTCHA math question:* 3 + 9 =

Thank you for completing the West Penn Allegheny Health System website survey.
We value your feedback and comments.